Today: 29 April 2026
Browse Category

NYSE:FICO 2 October 2025 - 29 April 2026

Top 10 Growth Stocks to Watch in Q2 2026 as AI Spending Faces Its Hardest Test Yet

Top 10 Growth Stocks to Watch in Q2 2026 as AI Spending Faces Its Hardest Test Yet

Microsoft, Alphabet, Amazon, and Meta are set to report earnings Wednesday, with investors watching for signs that heavy AI spending is driving growth. Visa posted a 17% rise in net revenue to $11.2 billion and announced a $20 billion buyback. T-Mobile raised 2026 guidance after service revenue climbed 11%. U.S. stocks fell Tuesday, with the Nasdaq down 0.90% as tech shares slipped.
29 April 2026
············
Grab stock edges higher in premarket as lidar deal and fintech rollout land ahead of earnings

Grab stock edges higher in premarket as lidar deal and fintech rollout land ahead of earnings

Grab shares rose 0.7% to $4.18 in premarket trading Friday after Hesai named Grab its exclusive lidar distributor in Southeast Asia. Grab Finance also launched automated credit decisioning across six countries using FICO’s platform. The company reports Q4 and full-year 2025 results after U.S. markets close on Feb. 11.
6 February 2026
······
Experian share price slides again as EXPN extends selloff in London

Experian share price slides again as EXPN extends selloff in London

Experian shares fell 1.3% to 2,749 pence in early London trading Wednesday, extending a four-day losing streak. The stock has dropped nearly 10% this week amid investor concerns over AI disruption, regulatory uncertainty, and Fair Isaac’s move to sell mortgage credit scores directly to lenders. Investors are watching for central bank signals and Experian’s February dividend.
28 January 2026
···
Fair Isaac Corp’s 2025 Surge: How a Direct‑to‑Lender Move Disrupted Credit Bureaus and Re‑Energized FICO Stock

Credit-Score Shake-Up! FICO Stock Rockets 20% on Game-Changing Strategy

FICO shares surged up to 23% in early October 2025 after launching a direct licensing model for its credit scores, bypassing credit bureaus. Q3 revenue rose 20% to $536.4 million, with net income at $181.8 million. Equifax, Experian, and TransUnion stocks fell as analysts warned of profit hits. FICO’s market cap reached $46 billion, with a trailing P/E of 69.
3 October 2025
····
Fair Isaac Corp’s 2025 Surge: How a Direct‑to‑Lender Move Disrupted Credit Bureaus and Re‑Energized FICO Stock

Fair Isaac Corp’s 2025 Surge: How a Direct‑to‑Lender Move Disrupted Credit Bureaus and Re‑Energized FICO Stock

FICO shares jumped about 10% in premarket trading on Oct. 2, 2025, after the company announced a Mortgage Direct License Program letting lenders access credit scores directly and cutting per-score fees. The stock closed at $1,512.71 on Oct. 1, down 24% year-to-date. FICO reported Q3 revenue of $536.4 million and non-GAAP EPS of $8.57 in July. Market cap stood at $36.4 billion.
2 October 2025
··

Stock Market Today

  • Humana Stock Dips Over 2% Amid Profit Forecast Revision
    April 29, 2026, 9:26 AM EDT. Humana Inc. (HUM) stock dropped more than 2% premarket after the health insurer maintained its adjusted full-year profit forecast at $9 per share but lowered its nonadjusted earnings estimate to at least $8.36 from $8.89. The company reported a 23% rise in first-quarter revenue and adjusted earnings per share beating expectations. However, charges from a multiyear transformation program to realign costs and operations weighed on results. Rising medical and pharmaceutical expenses, coupled with tighter government rules on Medicare Advantage payments, have pressured the sector. Humana, a major Medicare Advantage provider, faces ongoing margin challenges. Year to date, Humana shares have fallen about 13% amid these industry headwinds.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop